Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Information source: Allergan
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Ocular Hypertension
Intervention: brimonidine/timolol fixed combination (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Allergan
Summary
The purpose of this study is to assess the safety and efficacy of Brimonidine/Timolol Fixed
Combination in patients with glaucoma or ocular hypertension
Clinical Details
Study design: Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: IOP
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Clinical diagnosis of ocular hypertension or chronic glaucoma in both eyes
- Patient requires IOP-lowering drug in both eyes
Exclusion Criteria:
- Uncontrolled medical conditions
- contraindication to beta-adrenoceptor antagonist or brimonidine therapy
Locations and Contacts
Newport Beach, California, United States
Additional Information
Starting date: January 2000
Ending date: November 2001
Last updated: May 30, 2006
|
